Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma

British Journal of Urology

Volumn 80, Issue 4, 1997, Pages 543-547

  Kowalczyk, D ^a   Skorupski, W ^a,b   Kwias, Z ^a,b   Nowak, J ^a,b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Immunology; Renal cell carcinoma; Tumour infiltrating lymphocytes

Indexed keywords

CD4 ANTIGEN; HLA DR ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR VOLUME;

EID: 0031403224     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00408.x     Document Type: Article

References (25)

1. Finke JH, Rayman P, Alexander J et al. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell cancer. Cancer Res 1990; 50: 2363-70
2. Palmer PA, Vinke J, Evers P et al. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 1992; 28A: 1038-44
3. Kowalczyk D, Skorupski W, Kwias Z, Nowak J. Activated gamma/delta T lymphocytes infiltrating renal cell carcinoma patients. Immunol Lett 1996; 53: 15-8
4. Vose BM, Moore M. Human tumor-infiltrating lymphocytes: marker of host response. Semin Hematol 1985; 22: 27-40
5. Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991; 64: 631-44
6. Koo AS, Tso CL, Shimabukuro T, Peyret C, deKernion JB, Belldegrun A. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 1991; 10: 347-54
7. Chakraborty NG, Sporn JR, Pasquale DR, Ergin MT, Mukherji B. Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes. Clin Immunol Immunopathol 1991; 59: 407-16
8. Zeromski J, Dworacki G, Kruk-Zagajewska A, Szmeja Z, Jezewska E, Kostecka J. Assessment of immunophenotype of potentially cytotoxic tumor infiltrating cells in laryngeal carcinoma. Arch Immunol Ther Exp 1993; 41: 57-62
9. Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer 1990; 62: 971-5
10. Bilik R, Mor C, Hazaz B, Moroz C. Characterisation of T lymphocyte populations infiltrating primary breast cancer. Cancer Immunol Immunother 1989; 28: 143-7
11. Suzuki R, Handa K, Itoh K, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL2). I Proliferative response and establishment of cloned cells. J Immunol 1983; 130: 981-7
12. Sugamura K, Tanaka Y, Hinuma Y. Establishment of human cytotoxic T-cell lines specific for Epstein-Barr virus-transformed autologous cells. Int J Cancer 1981; 28: 137-42
13. Reed JC, Alpers JD, Nowell PC, Hoover RG. Sequential expression of protooncogenes during lecitin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci USA 1986; 83: 3982-6
14. Kronke M, Leonard WJ, Depper JM, Greene WC. Sequential expression of genes involved in human T lymphocyte growth and differentation. J Exp Med 1985; 161: 1593-8
15. Selli C, Hinshaw WM, Woodard BH, Paulson DF. Stratification of risk factors in renal cell carcinoma. Cancer 1983; 52: 899-903
16. Haas W, Pereira P, Tonegawa S. Gamma/delta cells. Annu Rev Immunol 1993; 11: 637-85
17. Alam SM, Clark JS, Leech V, Whitford P, George WD, Campbell AM. T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. Immunol Letters 1992; 31: 279-84
18. Gorczynski RM, Chen Z, Hoang Y., Rossi-Bergmann B. A subset of gamma delta T-cell receptor positive cells produce T-helper type-2 cytokines, and regulate mouse skin graft rejection, following portal venous pretransplant preimmunization. Immunology 1996; 87: 381-9
19. Dadian G, Riches PG, Henderson DC et al. Irnmunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 1994; 74: 15-22
20. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opinion Immunol 1995; 7: 704-10
21. Vose BM. Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumour site. Int J Cancer 1982; 30: 135-42
22. Kakiuchi T, Chesnut RW, Grey HM. B cells as antigen presenting cells: the requirments for B cell activation. J Immunol 1983; 131: 109-14
23. Mitropoulos D, Kooi S, Rodriguez-Villanueva J, Platsoucas CD. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derivied T cell lines from patients with renal cell carcinoma. Clin Exp Immunol 1994; 97: 321-7
24. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 1988; 42: 659-66
25. Kurt RA, Park JA, Panelli MC et al. T lymphocytes infiltrating sites of tumor rejection and progression display identical Vb usage but different cytotoxic activities. J Immunol 1995; 154: 3969-74